By: Laura Mildon
KLOW is a blend name used for a combination of KPV, BPC-157, TB-500, and GHK-Cu. It builds on the three-component combination commonly called GLOW by including KPV. These are separate molecular ingredients, each with its own research record. Combining them introduces a new question: what does the complete, characterized preparation do under defined experimental conditions?
The ingredient list explains the connection between the two blend names. It does not establish that KLOW produces a stronger effect than GLOW, or that results from individual ingredients transfer to the four-component combination. This article examines the terminology, chemistry, selected research, and evidence gaps.
“Stack” is informal vernacular for a combination of multiple peptides. People commonly use it when peptides are mixed together, as in a premixed blend. The word is also used more broadly for combinations discussed together even when the components are supplied separately. It is not a standardized chemical or regulatory term.
A blend describes materials physically combined in one preparation; a stack can be a broader informal description. Neither word establishes compatibility, synergy, or a validated scientific outcome. A useful description names the actual components and specifies whether the preparation is a mixture.
| Blend name | Commonly described components |
| GLOW | GHK-Cu plus BPC-157 plus TB-500 |
| KLOW | KPV plus BPC-157 plus TB-500 plus GHK-Cu |
These names do not define a universal composition, proportion, salt form, or analytical specification. In particular, TB-500 labeling may refer to a short fragment or use full-length thymosin beta-4 terminology. The exact identity must be checked rather than inferred from the blend name.
A mixture of four components has no single peptide sequence, molecular formula, or molecular weight that defines the KLOW name. Each specified ingredient needs its own chemical description. Freeze-drying components together does not, by itself, demonstrate that a new covalently linked molecule has formed.
An accurate molecular illustration would display the verified components separately, with the copper complex and TB-500 species clearly identified. Connecting four drawings into one peptide chain would depict a different chemical entity.
KPV stands for lysine-proline-valine. The letters are standard amino-acid abbreviations: K for lysine, P for proline, and V for valine. This sequence corresponds to the final three amino acid residues of alpha-melanocyte-stimulating hormone, or alpha-MSH, a longer signaling peptide. A sequence relationship does not mean the fragment reproduces every activity of the parent molecule.
| KPV identity feature | Description |
| Sequence shown here | H-Lys-Pro-Val-OH or H-KPV-OH |
| Length | 3 amino acid residues |
| Molecular formula | C₁₆H₃₀N₄O₄ for the parent free-acid peptide |
| Molecular weight | Approximately 342.43 g/mol |
| PubChem identifier | CID 125672 |
The terminal OH identifies a free carboxylic acid. Amidated versions have different terminal chemistry, while associated salts and water change the material specification. The formula above should not be assigned indiscriminately to every KPV preparation.
PubChem KPV identity sequence and authentic structural diagram
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV. Its parent formula is C₆₂H₉₈N₁₆O₂₂, with a molecular weight of approximately 1419.5 g/mol. Salt counterions and water require separate characterization.
PubChem BPC 157 chemical identity and structure
FDA’s assessment defines TB-500 as the N-acetylated seven-residue fragment Ac-LKKTETQ, related to positions 17 through 23 of thymosin beta-4. Its parent formula is C₃₈H₆₈N₁₀O₁₄, with a molecular weight of approximately 889.0 g/mol. Full-length thymosin beta-4 has 43 residues and is a different molecule. Evidence should follow the specified substance.
FDA chemical assessment of TB 500 and its acetate form
GHK is glycine-histidine-lysine. GHK-Cu describes a complex of this peptide with copper. Copper-to-peptide proportion, protonation, counterions, and water content matter when specifying a particular material. Copper-free GHK and a copper complex should not share an unqualified formula or molecular weight.
PubChem record for the GHK peptide ligand
KPV brings a literature on inflammatory signaling and experimental delivery systems into the discussion. Inflammation involves coordinated signals and cells, and its effects depend on timing and biological context. A decrease in one inflammatory marker does not establish better repair, broad immune protection, or a clinical benefit.
Dalmasso and colleagues investigated KPV in human intestinal epithelial and immune-cell lines and in two mouse models of colitis. They reported uptake through PepT1, a transporter that carries certain small peptides into cells, alongside reductions in NF-κB and MAP kinase signaling and inflammatory measurements. NF-κB is a regulator of gene activity involved in immune responses.
The paper appeared online in 2007 and in the January 2008 issue of Gastroenterology. Human-derived cell lines are laboratory models, not a clinical trial. The findings concern KPV in those systems, without the other three KLOW ingredients.
Dalmasso and colleagues on PepT1 mediated KPV uptake in Gastroenterology 2008
Xiao and colleagues incorporated KPV into hyaluronic-acid-functionalized nanoparticles and a hydrogel system. Experiments examined cellular uptake and inflammatory and tissue outcomes in a mouse colitis model. The findings concern a designed delivery formulation. A simple four-component peptide mixture is not equivalent to that nanoparticle system.
Xiao and colleagues in Molecular Therapy 2017
A 1988 GHK-Cu study reported increased collagen synthesis in fibroblast cultures. A 2014 BPC-157 study examined growth hormone receptor expression in rat tendon fibroblasts. These are component-specific cell experiments, rather than demonstrations of KLOW’s effects.
GHK Cu and collagen synthesis in fibroblast cultures 1988
BPC 157 and growth hormone receptor expression in tendon fibroblasts 2014
A 2024 TB-500 study compared the parent peptide and metabolites in a fibroblast wound-closure assay. Only the metabolite Ac-LKKTE showed significant activity compared with the control in that assay. This result illustrates why parent peptides, metabolites, and differently named related materials should remain distinct.
TB 500 metabolite and cell screening research 2024
These publications document research milestones for the ingredients. They do not establish an original inventor, discovery date, or validated formulation for KLOW. Nor does a paper about a peptide’s relationship to a natural sequence establish a history of the four-component blend.
The targeted literature search for this article did not identify a controlled clinical trial of a fully characterized KPV, BPC-157, TB-500, and GHK-Cu combination under the KLOW name. This search finding does not exclude every possible unpublished or differently indexed experiment. Published ingredient studies should retain their actual scope.
Comparing KLOW with GLOW would require matched formulations and appropriate controls to isolate the contribution of KPV. Merely adding a fourth component does not establish greater effectiveness, and an effect of the complete mixture would not identify which ingredient or interaction produced it.
Synergy means exceeding a defined expectation based on the individual components under a specified analytical model. Different mechanisms do not prove synergy or demonstrate that pathways never overlap. A 2019 methods study explains how reference models affect combination analysis; it did not test KLOW.
Additive response models and the definition of synergy 2019
Meaningful characterization identifies and measures each ingredient in the finished preparation and examines stability, degradation, or aggregation over the relevant study period. A single chromatographic purity percentage cannot establish every component’s identity, proportion, copper content, or stability. Endotoxin testing and sterility also answer different questions.
Composition stated by mass is not the same as composition by molecule count: the components have different molecular weights. Even identical ingredient names and total powder mass do not establish that two blends are chemically equivalent.
KLOW is not an FDA-approved medicine. FDA has identified important gaps in safety information for KPV and BPC-157 and concerns involving aggregation or impurities for certain peptide preparations, including injectable GHK-Cu. Its TB-500 assessment likewise describes inadequate safety and effectiveness evidence. Combining the ingredients does not resolve those gaps.
A compounding-list review or advisory recommendation is distinct from approval of a finished drug. Research labeling does not demonstrate biological safety or authorize a separate intended use.
FDA safety considerations for certain bulk substances including KPV
Research and regulatory sources checked October 15, 2026.
Because trust starts with real people, clear answers, and quality you can verify. We have a certified peptide specialist on staff, a phone number that connects you with a real human, and a physical location you can visit by appointment. Call or text us—we’re delighted to answer your questions and address your concerns. We also make checkout straightforward by accepting credit cards, without asking you to use cryptocurrency or connect your bank account to an unfamiliar payment app. And every peptide we sell is tested for purity and endotoxins by licensed U.S. laboratories, so you can choose your research peptides with confidence.
DISCLAIMER: These statements are for research purposes only and have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
All products offered by Trace Tides are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Trace Tides supplies products exclusively to qualified professionals and licensed research institutions. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
This website is restricted. To continue, please confirm you meet the minimum age requirement and accept the agreement below.
Both confirmations are required to continue. If you do not meet these requirements, please close this page.
